Fig. 1 · Structure

Documents & Downloads

Berberine Sulfate

Cat. No. A14812 CAS 633-66-9
Berberine Sulfate is an alkaloid which exhibits relatively weak antibiotic properties, because of its efflux by multidrug resistance pumps.

In Stock

Publications for Berberine Sulfate

2 publications citing this product

  1. Liyanage Manosika Buddhini Perera, .et al. , Biol Pharm Bull, 2024, 47(4):750-757 PMID: 38556260
  2. Mattia Mori, .et al. , ACS Omega, 2023, Aug 28;8(36):32424-32431 PMID: 37720761

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In RANKL-stimulated RAW264.7 reporter cells, berberine sulfate reduced NF-κB-dependent luciferase activity. The reported IC50 was approximately 5 μM after 1 h pretreatment and 6 h stimulation. This cellular readout does not establish a direct molecular target. [1]

Berberine sulfate was included in a recombinant HMGA–DNA displacement screen. At 100 μM, it showed no clear displacement of HMGA1 or HMGA2 from the E3 DNA probe in the representative EMSA. This negative result is specific to the tested assay conditions. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Berberine Sulfate Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Berberine Sulfate from 3 published references. In vitro models include recombinant HMGA1 or HMGA2 with ATTO 680-labeled E3 DNA probe; RAW264.7 cells stably carrying an NF-κB luciferase reporter.

Berberine Sulfate In Vitro Studies

Berberine sulfate inhibited RANKL-induced osteoclast formation in mouse bone marrow macrophage cultures over five days; the authors reported an IC50 of approximately 0.25 μM. A 48 h MTS control showed no viability loss through 10 μM, but its shorter duration does not exclude delayed toxicity during differentiation. [1]

Berberine sulfate in an HMGA–DNA displacement screen

Biochemical assay · Recombinant HMGA1 or HMGA2 with ATTO 680-labeled E3 DNA probe [2]

At 100 μM, compound 5 showed no clear displacement of the E3 DNA complexes in the representative EMSA. This is a qualitative negative screening result, not an IC50 or evidence of cancer-cell efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
HMGA1/E3 and HMGA2/E3 complex bands with compound 5Qualitative EMSA outcome No clear complex displacement at 100 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM
Exposure duration
Drug incubation 30 min after 30 min complex formation; incubations at 4 °C
Method
EMSA; Figure 1 uses HMGA1 1.56 pmol or HMGA2 0.78 pmol and E3 probe 0.05 pmol
Vehicle
10% DMSO final in shared EMSA method
Co-treatment
HMGA protein plus DNA; netropsin 10 μM positive and chloramphenicol 100 μM negative controls; probe-alone and protein–probe controls
Reported limits
Figure 1 replicate number not stated in the read experiment description. Shared method states 0.1 pmol oligonucleotide, whereas Figure 1 caption specifies 0.05 pmol; caption conditions retained without reconciliation.
Methods and source locations

Compound reported in the paper: Berberine sulfate; Compound label in the paper: Compound 5 (BBN125)

Results apply to the reported berberine sulfate material and experimental conditions; no A14812 lot equivalence is established.

Table 1 compound 5; Figure 1 (lane 15, label #5) and caption; In Vitro Evaluation of the HMGA/DNA-Displacing Activity; Experimental Section: compound 5 and EMSA

HMGA1/E3 and HMGA2/E3 complex bands with compound 5: Representative infrared-fluorescence EMSA; no band densitometry or potency estimate extracted — Figure 1, lane 15 (#5), both HMGA panels; Table 1; results identify compounds 16, 13 and 8 as active with E3

Inhibition of osteoclast differentiation with a viability control

Cell-based study · Primary bone marrow macrophages from C57BL/6 mice differentiated with M-CSF and RANKL [1]

Berberine sulfate reduced TRAcP-positive multinucleated osteoclast formation over five days. A separate 48 h MTS control showed no decrease in BMM viability through 10 μM; its shorter duration limits exclusion of delayed cytotoxicity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TRAcP-positive multinucleated osteoclast formationReported IC50 approximately 0.25 μM[1]
BMM metabolic viability after 48 h exposureMTS viability control No effect on viability at doses up to 10 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.25, 0.5, 1, 2.5, 5 and 10 μM
Exposure duration
5 days for differentiation; 48 h for MTS viability control
Method
TRAcP staining/counting following GST-rRANKL 50 ng/mL with M-CSF
Vehicle
Stock dissolved in DMSO; final DMSO fraction and explicit matched-vehicle treatment are not specified in the read methods
Co-treatment
RANKL-induced cultures compared with RANKL-treated drug-free controls; RANKL-negative control shown
Reported limits
Methods define osteoclast-like cells as TRAcP-positive multinucleated cells with more than 3 nuclei. Figure 1 n = 3; exact nesting of independent cultures and wells is not fully specified.
Methods and source locations

Compound reported in the paper: Berberine sulfate; Compound label in the paper: Berberine sulfate

Results apply to the reported berberine sulfate material and experimental conditions; no A14812 lot equivalence is established.

Results 2.1; Figure 1B–E and caption; Methods 4.1–4.4 and 4.9

TRAcP-positive multinucleated osteoclast formation: Author-reported estimate, not calculated from the image; Figure 1D n = 3, data mean ± SEM per Methods 4.9; treated groups marked *** p < 0.001 versus RANKL-treated control — Results 2.1 and Discussion; Figure 1D; Methods 4.3 and 4.9

BMM metabolic viability after 48 h exposure: MTS absorbance at 490 nm; Figure 1E n = 3; control duration 48 h, not the 5-day differentiation duration — Results 2.1; Figure 1E; Methods 4.4

Suppression of RANKL-stimulated NF-κB reporter activity

Cell-based study · RAW264.7 cells stably carrying an NF-κB luciferase reporter [1]

Reporter activity was significantly reduced from 1 μM, with an author-reported approximate IC50 of 5 μM. This supports an effect on a cellular signaling readout, without identifying a directly bound molecular target.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RANKL-induced NF-κB transcriptional luciferase activityReported IC50 approximately 5 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.25, 0.5, 1, 2.5, 5 and 10 μM
Exposure duration
1 h pretreatment, followed by 6 h RANKL stimulation
Method
NF-κB-dependent luciferase assay with GST-rRANKL 50 ng/mL
Vehicle
DMSO stock; final vehicle percentage not specified
Co-treatment
RANKL-stimulated drug-free and RANKL-negative controls shown
Reported limits
Figure 4A n = 6; shared statistics say mean ± SEM with at least 3 independent experiments, but well/experiment nesting is not fully resolved. No orthogonal luciferase-interference control established in the read scope.
Methods and source locations

Compound reported in the paper: Berberine sulfate; Compound label in the paper: Berberine sulfate

Results apply to the reported berberine sulfate material and experimental conditions; no A14812 lot equivalence is established.

Results 2.4; Figure 4A and caption; Methods 4.1, 4.2, 4.7 and 4.9

RANKL-induced NF-κB transcriptional luciferase activity: Results 2.4 estimate; Figure 4A shows reduction from 1 μM. Figure n = 6, mean ± SEM under Methods 4.9 — Results 2.4; Figure 4A and caption; Methods 4.7 and 4.9

Berberine Sulfate In Vivo Studies

In male Sprague–Dawley rats, oral berberine sulfate at 10 mg/kg as berberine gave bioavailability of 0.26 ± 0.01%. Rectal doses of 1, 3 and 10 mg/kg as berberine gave 17.0 ± 4.9%, 24.3 ± 5.6% and 12.3 ± 4.4%, respectively (mean ± S.D.; 3 oral and 4 rectal trials). These formulation-dependent pharmacokinetic findings do not establish disease efficacy. [3]

Route-dependent plasma exposure to berberine sulfate

Animal study · Male Sprague–Dawley rats, 9 weeks old, fasted overnight; oral, rectal and intravenous route comparison [3]

Oral bioavailability was low; rectal suppositories increased exposure relative to oral dosing. Rectal bioavailability was highest at 3 mg/kg as BBR and lower at 10 mg/kg. This pharmacokinetic study did not test disease efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Dose-normalized plasma bioavailability, using IV referenceBioavailability Oral 10 mg/kg: 0.26 ± 0.01%; rectal 1, 3, 10 mg/kg: 17.0 ± 4.9%, 24.3 ± 5.6%, 12.3 ± 4.4%, respectively (doses as BBR)[3]

Conditions shared by the study groups

Frequency
Single administration
Treatment course
Plasma sampling through 8 h for oral/rectal routes; IV AUC extrapolated to infinity
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Intravenous reference
1 mg/kg as BBR; Figure 1 explicitly reports 1.29 mg berberine sulfate/kg
Reference for dose-normalized bioavailabilityAUC0–∞ 160.7 ± 35.9 ng·h/mL; F assigned 100%; Figure 1 n = 4 trials[3]
Oral 10 mg/kg as BBR
10 mg/kg as BBR; Figure 2 explicitly reports 12.9 mg berberine sulfate/kg
IV reference; oral comparator for rectal groupsF 0.26 ± 0.01%; Cmax 0.94 ± 0.10 ng/mL; AUC0–8h 4.1 ± 0.2 ng·h/mL; n = 3 trials[3]
Rectal 1 mg/kg as BBR
1 mg/kg as BBR
IV reference and oral 10 mg/kg as BBRF 17.0 ± 4.9%; Cmax 9.62 ± 5.04 ng/mL; AUC0–8h 27.3 ± 7.9 ng·h/mL; n = 4 trials; F ** p < 0.01 versus oral[3]
Rectal 3 mg/kg as BBR
3 mg/kg as BBR
IV reference and oral 10 mg/kg as BBRF 24.3 ± 5.6%; Cmax 29.4 ± 7.2 ng/mL; AUC0–8h 117.1 ± 26.8 ng·h/mL; n = 4 trials; F ** p < 0.01 versus oral[3]
Rectal 10 mg/kg as BBR
10 mg/kg as BBR; Figure 2 explicitly reports 12.9 mg berberine sulfate/kg
IV reference, oral 10 mg/kg and rectal 3 mg/kg as BBRF 12.3 ± 4.4%; Cmax 57.0 ± 18.0 ng/mL; AUC0–8h 197.3 ± 71.3 ng·h/mL; n = 4 trials; F * p < 0.05 versus oral and † p < 0.05 versus rectal 3 mg/kg[3]
Intravenous reference
Model: Male Sprague–Dawley rats, 9 weeks old, fasted overnight; oral, rectal and intravenous route comparison
Route: Intravenous
Reported limits: IV vehicle not specified in the read Animal Studies section.
Oral 10 mg/kg as BBR
Model: Male Sprague–Dawley rats, 9 weeks old, fasted overnight; oral, rectal and intravenous route comparison
Route: Oral
Vehicle: 0.5% sodium carboxymethyl cellulose solution
Rectal 1 mg/kg as BBR
Model: Male Sprague–Dawley rats, 9 weeks old, fasted overnight; oral, rectal and intravenous route comparison
Route: Rectal
Vehicle: Witepsol H15 suppository base
Rectal 3 mg/kg as BBR
Model: Male Sprague–Dawley rats, 9 weeks old, fasted overnight; oral, rectal and intravenous route comparison
Route: Rectal
Vehicle: Witepsol H15 suppository base
Rectal 10 mg/kg as BBR
Model: Male Sprague–Dawley rats, 9 weeks old, fasted overnight; oral, rectal and intravenous route comparison
Route: Rectal
Vehicle: Witepsol H15 suppository base
Methods and source locations

Compound reported in the paper: Berberine sulfate; Compound label in the paper: BBR sulfate

Results apply to the reported berberine sulfate material and experimental conditions; no A14812 lot equivalence is established.

Materials and Methods: Materials, Animal Studies, LC-MS/MS, Estimation of Pharmacokinetic Parameters, Statistical Analysis; Results; Table 1 with footnotes; Figures 1–2

Dose-normalized plasma bioavailability, using IV reference: Table 1 mean ± S.D.; n = 3 oral and n = 4 rectal trials. Rectal 1/3 mg/kg ** p < 0.01 versus oral; rectal 10 mg/kg * p < 0.05 versus oral and † p < 0.05 versus rectal 3 mg/kg. F uses AUC0–8h for extravascular routes, AUC0–∞ for IV — Table 1 bioavailability row and footnotes; Estimation of Pharmacokinetic Parameters

Intravenous reference · Table 1 and footnotes; Materials and Methods: Animal Studies; Figure 1/2 captions

Oral 10 mg/kg as BBR · Table 1 and footnotes; Materials and Methods: Animal Studies; Figure 1/2 captions

Rectal 1 mg/kg as BBR · Table 1 and footnotes; Materials and Methods: Animal Studies; Figure 1/2 captions

Rectal 3 mg/kg as BBR · Table 1 and footnotes; Materials and Methods: Animal Studies; Figure 1/2 captions

Rectal 10 mg/kg as BBR · Table 1 and footnotes; Materials and Methods: Animal Studies; Figure 1/2 captions

Specifications

Manufacturer Adooq Bioscience
CAS Number 633-66-9
Formula C20H19NO8S
Molecular Weight 433.43
Synonyms Berberine Hemisulfate
SMILES
COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC.OS(=O)(=O)[O-]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 19 mg/mL (43.83 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Berberine Sulfate Research References

  1. [1] Lin Zhou, Fangming Song, Qian Liu, et al. Berberine Sulfate Attenuates Osteoclast Differentiation through RANKL Induced NF-κB and NFAT Pathways International Journal of Molecular Sciences (2015). PMID: 26580592 DOI: 10.3390/ijms161125998 Source material
  2. [2] Mattia Mori, Francesca Ghirga, Beatrice Amato, et al. Selection of Natural Compounds with HMGA-Interfering Activities and Cancer Cell Cytotoxicity ACS Omega (2023). PMID: 37720761 DOI: 10.1021/acsomega.3c02043 Source material
  3. [3] Nobuhiro Mori, Keisuke Oda, Hideki Takakura, et al. Comparison of Berberine Bioavailability between Oral and Rectal Administrations in Rats Biological and Pharmaceutical Bulletin (2023). PMID: 37914368 DOI: 10.1248/bpb.b23-00444 Source material

Publications

2 publications citing this product

  1. Liyanage Manosika Buddhini Perera, .et al. , Biol Pharm Bull, 2024, 47(4):750-757 PMID: 38556260
  2. Mattia Mori, .et al. , ACS Omega, 2023, Aug 28;8(36):32424-32431 PMID: 37720761

Added to your cart

View Cart Checkout
Loading...